Latest Headlines

Latest Headlines

UPDATED: Celladon's heart drug grabs 'breakthrough' status at FDA

San Diego-based Celladon has nabbed a "breakthrough" drug designation from the FDA for its heart failure drug Mydicar. The gene therapy uses a benign virus to insert the Serca2a gene into heart cells.

Biotech's breathless quarter of IPOs brings in $2.1B for R&D

Back in January, at the annual J.P. Morgan Healthcare Conference, across hotel lobbies and crowded hallways and standing-room-only cafes, one could hardly escape talk about the biotech IPO boom.

Trio of IPO setbacks strike sour note at biotech's Wall Street party

In a fresh sign that the big biotech IPO wave that triggered a long lineup of dazzling debuts may have crested, two new California contenders have had to significantly scale down their expectations and a third has decided to bow out for now.

Celladon swings for $92M in up-charged IPO

2012 Fierce 15 member Celladon has boosted its IPO goals, seeking as much as $92 million to help get its gene therapy for heart failure through a Phase IIb study and into Phase III.

Celladon, Xencor bid for $155M in red-hot IPO market

Celladon and Xencor have cast lines into the still-blazing biotech IPO scene, seeking a combined $155.3 million and betting that the recent Wall Street excitement for drug developers will hold firm.

Celladon's gene therapy for heart failure takes spotlight in the U.K.

San Diego-based Celladon has made a big splash in the U.K. British scientists are playing a prominent role in a pair of clinical trials of Celladon's Mydicar, a gene therapy for heart failure which uses a benign virus to insert the Serca2a gene into heart cells.

Defining 'fierce' in the modern age of drug and device development

Now, more than ever, the life sciences industry is all about innovative and disruptive technologies. Every year for the past decade, FierceBiotech has made its picks on which companies hold the best odds for success in our Fierce 15 report. This year, though, we've added another Fierce 15 to focus on medical devices and diagnostics. I'd like to encourage readers to consider the differences by comparing the companies in each report.

FierceBiotech's 2012 Fierce 15 at BioPharm America

Nick Leschly, the CEO of Bluebird Bio, playfully dubbed the ambitious spirit of biotechs Levin Syndrome, a fictional affliction named after Third Rock Ventures' Mark Levin that compels biotech entrepreneurs to, as they say, go big or go home. Our Fierce 15 companies are all "going big." They also went home… with trophies. Check out the slideshow below.

The Fierce 15: An appetite for risk is healthy in drug development

There's more than one way to build a biotech company. And this year's Fierce 15 companies reflect a range of companies operating with a spectrum of business models. Here's the full report >>   Click here to view a video of FierceBiotech Editor John Carroll announcing the Fierce 15 at BioPharm America >>  

H1 venture deals: Celladon moves up in the rankings

After we published our list on the top 15 venture deals of H1 2012, the folks at Celladon dropped us a note to say that they did bank the full $53 million venture round in the period, which includes a $10 million extension, rather than the tranche we reported. So Thomson Reuters is updating its records, and so are we.